Supported by
Built with world-class partners
Discovery, manufacturing, preclinical and academic partners advancing FTX-2802.
Finn Therapeutics is pioneering first-in-class antibodies that remodel the tumour stroma and microenvironment — disrupting the support system that lets hard-to-treat solid tumours resist therapy — to improve outcomes for patients with limited options.
Solid tumours build a supportive microenvironment — the stroma — that fuels their growth, shields them from the immune system, and helps them spread. Today's checkpoint inhibitors and TKIs largely leave this support system intact.
We focus on a tumour-associated target within the microenvironment that is distinct from existing approaches — offering a tumour-specific opportunity with a well-defined safety window.
FTX-2802 is a humanised IgG1 antibody designed to selectively disrupt the signalling that sustains the tumour-supporting microenvironment.
Biomarker-led patient selection focuses development on those most likely to respond — a leaner, impactful route to a meaningful clinical signal.
The tumour microenvironment simultaneously promotes new blood-vessel formation, suppresses anti-tumour immunity, and drives the lymphatic spread of disease — three of the primary ways solid tumours evade therapy.
FTX-2802 is a first-in-class antibody designed to disrupt this tumour-supporting biology, offering a mechanism-differentiated approach intended to work alongside existing standard-of-care therapies.
Request the science overview →Our lead programme, FTX-2802, is advancing through preclinical development toward clinical proof of concept.
FTX-2802 is an investigational medicine and is not approved for clinical use.
Finn Therapeutics is an asset-centric, virtual biotech registered in the UK, advancing a first-in-class antibody programme that targets the tumour microenvironment. We work globally with leading academic and contract research partners to develop FTX-2802 with discipline, laser focus and capital efficiency.
Our mission is simple: to improve outcomes for patients whose cancer no longer responds to existing treatment — and to build a company whose success rewards those who back it early.
A new target with no approved therapy.
Focused on treatment-resistant solid tumours.
Patent application filed for the programme.
Outsourced, milestone-driven model.
Discovery, manufacturing, preclinical and academic partners advancing FTX-2802.
We share detailed information with qualified investors and partners on a confidential basis. Whether you're an investor, a potential collaborator, or a scientist in the field — we'd like to hear from you.